Каталог

LOW-INTENSITY PULSED LIGHT REDUCES SKIN SENSITIVITY

 

Symptoms that are not always visible

Sensitive skin is a condition in which ordinary triggers produce a disproportionately strong response: burning, stinging, tightness, itching, a sensation of heat. Visible redness may be present or absent: judging by complexion alone, or by the patient's words alone, means seeing only half the picture.

Sensitivity rarely exists on its own: it accompanies rosacea, acne and dermatitis, and develops against a background of a compromised barrier and aggressive skincare. So whether these patients can be offered an energy-based procedure, and in what mode, is one of the most practical questions. That is exactly the question the authors of the Journal of Cosmetic Dermatology paper posed.

 

Study details

Fu and colleagues (2025) reviewed the records of patients treated in the dermatology department of Tianjin Medical University Hospital (China) between January 2019 and January 2022 [1]. This was a retrospective analysis: the authors worked with existing charts rather than enrolling participants under a protocol. The study had no control group and no randomization; only the two physicians who graded the photographs on the erythema scale were blinded.

Participants. The sample comprised 181 people: 24 men and 157 women aged 16 to 53 years, mean age 31.42 ± 8.18 years. Nearly all participants had Fitzpatrick skin type III (126 people, 70%) or IV (55, 30%), that is, fair to moderately tanned skin. There were four groups: isolated sensitive skin (86), rosacea (32), acne (32), and dermatitis (31) with sensitive skin.

Devices and treatment parameters. Treatments were delivered on a Brilliant Laser Photonics Workstation (Alma Lasers) in DPL mode — low-intensity pulsed light at 500–600 nm. This is a modification of IPL: a filter cuts out the out-of-band portion of the spectrum. It passes only the 500–600 nm window, and the authors classify the format itself as photomodulation — exposure to low-energy light of a narrow spectrum. Energy density was 5.0–6.8 J/cm², pulse duration 10–15 ns, spot size 6 mm, cooling 50%. Parameters were set individually, taking into account the type of changes, skin color, skin type, and the patient's response: the guide was the patient's sensation (no discomfort or mild warmth was acceptable), and the clinical endpoint was no visible reaction or mild erythema. A course consisted of two to four sessions about four weeks apart. Immediately after the procedure, the skin was cooled for 20 minutes.

Home care was an important part of the protocol: patients were advised to use soothing masks for 15 minutes daily for one week, avoid irritating products, moisturize, use barrier creams, cleanse with water, and follow strict photoprotection.

Assessment methods. Three instruments were used, and the results were additionally converted into an efficacy index; safety was recorded separately. The Sensitive Scale-10 (SS-10) consists of 10 items scored 0 to 10 and is completed by the patient [2]: it covers redness and subjective symptoms — skin reactivity, stinging, burning, tightness, itching, pain, general discomfort, hot flashes. The paper lists nine wordings against the stated ten items, so the full list cannot be reconstructed from the text. The scale was administered at baseline and after the last session, and symptoms were rated for the preceding three days. The Clinician Erythema Assessment (CEA) grades erythema from 0 (clear skin, no erythema) to 4 (severe erythema with marked redness) [3]; two blinded physicians graded photographs at every visit. VISIA-CR (Canfield Scientific, USA) analyzed red areas of the face in three projections — frontal and both lateral. The efficacy index (EI) was calculated from total SS-10 scores: (score before treatment − score after treatment) / score before treatment × 100%, with four categories — recovery at EI ≥ 90%, marked effect at 60% ≤ EI < 90%, improvement at 30% ≤ EI < 60%, no effect at EI < 30%. Adverse reactions — pain, burning, redness, swelling, blistering, and scarring — were recorded at every visit.

 

Results: symptoms improved, but not equally

Subjective symptoms (SS-10). Total scores fell in all four groups, in every case significantly (p < 0.001): isolated sensitive skin — from 18.15 ± 8.40 to 5.66 ± 4.40; acne with sensitive skin — from 19.81 ± 8.95 to 6.91 ± 4.44; dermatitis with sensitive skin — from 26.65 ± 9.44 to 9.03 ± 6.35; rosacea with sensitive skin — from 31.16 ± 9.07 to 14.59 ± 7.41.

Two things follow. First, the group that started most severe — rosacea — remained the most severe after the course, with a final score more than twice that of isolated sensitive skin. Second, the relief was incomplete: redness, reactivity, stinging, burning, tightness, itching, general discomfort, and hot flashes improved significantly (p < 0.05), while pain showed no change (p > 0.05).

Objective erythema. Both instrumental assessments showed consistent results. On the CEA, the change between visits was significant in all groups (p < 0.001); the authors report the actual means only in a table, not in the text. On VISIA-CR, values fell in all three projections and in all groups (p < 0.001). For isolated sensitive skin: frontal projection — from 41.92 ± 10.49 to 34.33 ± 10.14, left — from 46.97 ± 7.17 to 39.19 ± 6.82, right — from 46.27 ± 7.08 to 37.84 ± 6.61.

The composite "overall efficacy." The authors report 97% for isolated sensitive skin, 91% for acne, 97% for dermatitis, and 78% for rosacea. The mechanics matter more than the number: the efficacy index was calculated from total SS-10 scores, and "effective" cases pooled recovery (a reduction of at least 90%), marked improvement (60–89%) and improvement (30–59%); anything below 30% was classed as ineffective. So the 97% also includes patients whose score dropped by only a third — it is not the proportion of patients whose symptoms resolved completely.

Tolerability: redness, swelling and what stayed off the record. Immediately after the procedure, most patients developed redness, which subsided noticeably after cooling. Some patients developed facial swelling that resolved within three days. The authors recorded no blistering, pigmentary changes, or scarring. The paper provides no numerical frequencies: it does not state how many patients developed redness or swelling. "Most" and "some" are all the text provides.

The practical takeaway: the tolerability profile looks favorable. Still, it rests on qualitative descriptions rather than counted proportions, and data on skin barrier status do not support it.

 

Limitations: why 97% does not mean "everyone cured"

The main limitation is the absence of a control group: without one, the effect of light cannot be separated from home care, avoidance of irritating products, photoprotection, and the natural course of the condition. The authors state outright that some patients may have improved over time, and they call for prospective controlled studies.

Second, the retrospective design and incomplete data. The number of sessions varied (two to four), and the authors do not state how many patients received exactly two, three, or four; the number of patients at different visits changed, so the erythema tables should not be read as a follow-up of all 181 people after an identical course.

Third, the sample: a single center, mostly women, only skin types III and IV, few men — which the authors acknowledge. There are no data at all for skin types V–VI, and that is precisely where safety questions in phototherapy are most acute.

Fourth, mechanism. The discussion lists possible explanations: absorption of light by hemoglobin, effects on blood vessels, changes in inflammatory responses, fibroblast activity and collagen synthesis, barrier state, the microbiome, neurovascular reactivity. These are hypotheses supported by other publications, not measurements made in this study.

 

What to take into practice and what to wait on

The practical value of the work lies not in the 97% but in how it frames the question. Below are four conclusions that can be carried into the clinic, and one that should wait.

Assess two independent outcomes. In sensitive skin, the patient's sensations (SS-10) and objective erythema (CEA, VISIA-CR) should be evaluated separately. Improvement in one does not guarantee improvement in the other: here the scales moved in step, yet pain showed no significant change at all. "It feels better," and visible redness are different clinical problems.

Rosacea is a separate category. Here both the baseline severity was highest and the result most modest: 78% versus 91–97% in the other groups. A course for these patients should be planned differently — with more cautious expectations and, probably, more sessions.

Care is part of the treatment, not an add-on. Barrier products, daily masks, avoidance of irritating formulations and photoprotection were built into the protocol, not attached to it. Without that framework, the contribution of the procedure itself cannot be assessed.

Parameters do not transfer automatically. The 500–600 nm range and the 5.0–6.8 J/cm² energy density describe one specific protocol on one specific device (Brilliant Laser Photonics Workstation, Alma Lasers) in patients with skin types III–IV. They are not a universal setting for another device, another skin type, or another condition.

What the study does not show. It does not demonstrate superiority over home care, drug therapy, or other light regimens — for the reasons listed under limitations. The accurate wording is therefore "was accompanied by a reduction in symptoms and erythema with reactions expected of phototherapy," not "proven efficacy."

Bottom line for practice. The direction looks promising and deserves a focused prospective study with a control arm. Still, for now, it supports careful patient selection and an honest conversation about what is established, what remains a hypothesis, and what alternatives exist.

 

References

  1. Fu Y., Quan Y., Zhao W. et al. Low-energy delicate pulsed light therapy for sensitive skin: a retrospective study. J Cosmet Dermatol 2025; 24: e16781.
  2. Misery L., Jean-Decoster C., Mery S. et al. A new ten-item questionnaire for assessing sensitive skin: the Sensitive Scale-10. Acta Derm Venereol. 2014; 94(6): 635–639.
  3. Tan J., Liu H., Leyden J.J., Leoni M.J. Reliability of Clinician Erythema Assessment grading scale. J Am Acad Dermatol 2014; 71(4): 760-763.
Along with these articles also read